Table 1 Clinical characteristics of all patients

Age

 Median (range), years

65 (34–89)

65 (34–89)

57.5 (35–77)

Sex

 Male

82

46.3

69

44.5

13

59.1

 Female

95

53.6

86

55.4

9

40.9

Smoking status

 Never-smoker

93

52.5

84

54.2

9

40.9

 Current or former smoker

79

44.5

66

42.5

13

59.1

 Unknown

5

2.8

5

3.2

0

0

 Pack-years^aMedian (range)

26 (2–114)

27 (2–114)

17 (5–60)

ECOG performance status

 0

96

54.2

83

53.5

13

59.1

 1

54

30.5

46

29.6

8

36.4

 2

11

6.2

11

7.1

0

0

  > 2

10

5.5

9

5.8

1

4.5

 Unknown

6

3.3

6

3.8

0

0

Tumor histology

 Adenocarcinoma

165

93.2

145

93.5

20

90.9

 Adenosquamous carcinoma

4

2.2

4

2.6

0

0

 Squamous

2

1.1

1

0.64

1

4.5

 NSCLC, NOS

2

1.1

1

0.64

1

4.5

 Pleomorphic carcinoma

1

0.56

1

0.64

0

0

 Unknown

3

1.6

3

3.9

0

0

Stage

 Postoperative relapse

72

40.6

64

41.3

8

36.4

 III

8

4.5

4

2.6

4

18.2

 IV

97

54.8

87

56.1

10

45.4

Presence of extrathoracic metastases^{b c}

 Yes

113

63.8

100

64.5

13

59.1

 No

64

36.1

55

35.4

9

40.9

Presence of brain metastases^b

 Yes

45

25.4

41

26.4

4

18.2

 No

132

74.5

114

73.5

18

81,8

Treatment

All

EGFR-Mutated

ALK-Rearranged

Number of chemotherapeutic regimens, Median

3 (1–14)

3 (1–14)

3 (1–9)

(range)

2(0–7)

2 (0–7)

1 (0–4)

Molecular targeted drugs

1 (0–7)

1 (0–7)

1 (0–5)

Cytotoxic chemotherapy

Immunotherapy

0 (0–2)

0 (0–2)

0 (0–1)